Endocrinology Search
Endocrinology Endocrinology
obesity
OBESITY
Obesity is having an excessive amount of body fat in relation to lean body mass that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include to lose 5-10% of body weight or 0.5-1 kg (1-2 lb)/week for 6 months and regain of <3 kg in 2 years and sustained reduction of waist circumference of at least 4 cm.
Strategies are aiming for realistic goals and a multidisciplinary approach that is a combination of dietary change, physical activity and behavioral modification.
Drug Information

Indication: Adjunctive therapy to diet in patients w/ obesity & BMI ≥30, who have not responded to an appropriate w...

Indication: Short-term adjunct in the management of obesity in a medically monitored comprehensive regimen of wt reduction...

Indication: Iin conjunction w/ a mildly hypocaloric diet for obese (BMI ≥30 kg/m2) & overwt (BMI ≥28 ...

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Febuxostat bests allopurinol, benzbromarone in lowering cholesterol, triglycerides in gout patients
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Weight loss could sustain T2D remission for 2 years
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

Original New Drug Application Approvals by US FDA (16 - 31 July 2019)
31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Long-term cortisol exposure tied to short stature, increased cholesterol in Turner syndrome
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.